Catalog No.
KAV00109
Description
This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant SARS-CoV-2 Spike Protein (Trimer) has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Human Anti-SARS-CoV-2 Spike Protein (Trimer) IgG present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Human Anti-SARS-CoV-2 Spike Protein (Trimer) IgG bound in the initial step. The color development is stopped and the intensity of the color is measured.
Target
Spike
Applications
Used for the quantitative determination of Anti-SARS-CoV-2 Spike Protein (Trimer) Human IgG concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
125 - 8,000 pg/mL
Sensitivity
54.8 pg/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (pg/mL)
|
2802.1
|
561.9
|
146.7
|
3509.3
|
606.9
|
161.6
|
|
Standard deviation
|
104.5
|
26.5
|
12.8
|
301.1
|
50.9
|
18.2
|
|
CV (%)
|
3.7
|
4.7
|
8.7
|
8.6
|
8.4
|
11.2
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
Characteristics of Kawasaki disease in children with a history of COVID-19., PMID:40517900
Covalent Functionalization of Layered Double Hydroxides to Generate Peptide-Based SARS-CoV-2 Nanovaccine., PMID:40508447
Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720
Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2., PMID:40481111
Serum Levels of IL-21 and IL-27 Do not Reflect differential Avidity of Anti-SARS-CoV-2 IgG Antibodies in Symptomatic and Asymptomatic COVID-19 Patients., PMID:40471646
Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929
Antibody Response Against SARS-CoV-2 Spike Protein in People with HIV After COVID-19 Vaccination., PMID:40432092
Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652
Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies., PMID:40430736
Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate., PMID:40425664
Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains., PMID:40408899
Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster., PMID:40406109
The Combination of TLR4 and TLR9 Agonists with Self-Amplifying RNA Lipid Nanoparticles Leads to a More Powerful Immune Response Against SARS-CoV-2., PMID:40401447
Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus., PMID:40398376
Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination., PMID:40386778
Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity., PMID:40359129
Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals., PMID:40358138
Mimicking immune complexes for efficient antibody responses., PMID:40356891
Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID., PMID:40346201
Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies., PMID:40346118
Identifying Neurological Autoantibodies in COVID-19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China., PMID:40343769
Engineered bacteria as an orally administered anti-viral treatment and immunization system., PMID:40340796
Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with lung infection and tissue-damage biomarkers., PMID:40339608
Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein., PMID:40338637
Using SARS-CoV-2 red cell kodecytes to assess vaccine-induced immune response to the conserved 1147-58 region of the spike protein in Indian blood donors: exploring the potential role of blood transfusion services in population surveillance., PMID:40335014
Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients., PMID:40328892
Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination., PMID:40326950
Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination., PMID:40311214
SARS-CoV-2 S1 protein induces IgG-mediated platelet activation and is prevented by 1.8-cineole., PMID:40306177
A T7 autogene-mediated DNA vaccine platform for SARS-CoV-2: Overcoming DNA vaccine limitations with enhanced spike mRNA production., PMID:40287096
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013
Evaluation of mRNA Transfection Reagents for mRNA Delivery and Vaccine Efficacy via Intramuscular Injection in Mice., PMID:40263125
Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge., PMID:40258004
Dual-screen-printed electrode platform for simultaneous detection of IgG and IgM antibodies using magnetic beads nanocomplexes., PMID:40250514
Nasal delivery of killed Bacillus subtilis spores protects against influenza, RSV and SARS-CoV-2., PMID:40242757
Modifying the glycosylation profile of SARS-CoV-2 spike-based subunit vaccines alters focusing of the humoral immune response in a mouse model., PMID:40217109
Spike specific IgG3 and nucleocapsid IgG response in serum serve as distinguishing immunological markers between SARS-CoV-2 infection and vaccination., PMID:40213555
Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study., PMID:40185990
Neutralizing antibody responses after a two-dose regimen with BNT162b2, CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants., PMID:40185297
Exploring TLR agonists as adjuvants for COVID-19 oral vaccines., PMID:40184639
Study protocol for a randomised controlled trial evaluating the efficacy of dietary modulation of probiotics on nutritional status and antibody response to SARS-CoV-2 in Indonesian adolescents: gut-lung axis (DIVINE)., PMID:40180370
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial., PMID:40179522
Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery., PMID:40163903
Virus-specific antibody responses in severe acute respiratory syndrome coronavirus 2-infected and vaccinated individuals., PMID:40157431
Optimizing Clinical Management of COVID-19: A Predictive Model for Unvaccinated Patients Admitted to ICU., PMID:40137715
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma., PMID:40133428
Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination., PMID:40132457
Enhanced Humoral and Cellular Immune Responses Elicited by Salmonella Flagellin-Adjuvanted SARS-CoV-2 S1 Subunit Vaccine., PMID:40127244
Immunological assessment of NSFu1: A novel fusion molecule constructed from structural proteins of SARS-CoV-2 for improving COVID-19 antibody detection., PMID:40088274
 IgG ELISA Kit-antibodysystem.jpg)
For research use only. Not for human or drug use.
